Category: Fellows Posters
This retrospective review and drug information (DI) resource use evaluation will assess the utility and impact of the FAERS Public Dashboard in an academic DI center.
The FAERS Public Dashboard was used for 32 DI consultations, under 4% of the 826 requests received over the 20-month period. The median number of consultations using FAERS data per month doubled from the first 10-month period to the second period. FAERS was used alone or in conjunction with other resources for 17.5% of all adverse event-related requests (26 of 148 requests). While all consultations included other resources in their systematic search, only 5 used findings from FAERS alone. Primary or review literature (84%), drug handbooks (84%), prescribing information (44%), and Meyler’s Side Effects of Drugs (22%) were commonly used in conjunction with FAERS for these consultations. Of the 32 consultations, 29 (91%) consultations reported findings from FAERS, at minimum the number of reports of the adverse event of interest occurring in a patient receiving the drug of interest. The total number of adverse event reports for the drug of interest, the number of serious or fatal events for the event and drug of interest, and other data from individual case listings, were included in 79%, 21%, and 14% of consultations, respectively. FAERS data was discussed in 79% of conclusions and cited as evidence for all 8 recommendations given.
While the FAERS Public Dashboard is not consistently being used for adverse effect-related requests submitted to our DI service, its utilization is increasing. When the FAERS Public Dashboard is included in systematic searches to address DI requests, a majority of the overall consultation conclusions and/or recommendations are informed by the FAERS data identified, suggesting that this resource is useful for addressing adverse effect-related requests. However, FAERS data alone is rarely sufficient to adequately address these requests. Instead, FAERS data seems to be best utilized in conjunction with other resources, including drug handbooks, primary literature or reviews, and package inserts.